Baili Tianheng announced that the company has received the “Drug Registration Certificate” from the State Drug Administration, and the self-developed marketing application for the world's first EGFR × HER3 dual antibody ADC Renkang ilontuzumab/Yizekang advanced second-line esophageal cancer has been approved. This is the second indication that the drug has been approved in China. Previously, it was approved for marketing to treat recurrent or metastatic nasopharyngeal cancer, and marketing applications for locally advanced or metastatic triple-negative breast cancer have also been accepted. Drug sales are uncertain due to factors such as policies and markets.

Baili Tianheng announced that the company has received the “Drug Registration Certificate” from the State Drug Administration, and the self-developed marketing application for the world's first EGFR × HER3 dual antibody ADC Renkang ilontuzumab/Yizekang advanced second-line esophageal cancer has been approved. This is the second indication that the drug has been approved in China. Previously, it was approved for marketing to treat recurrent or metastatic nasopharyngeal cancer, and marketing applications for locally advanced or metastatic triple-negative breast cancer have also been accepted. Drug sales are uncertain due to factors such as policies and markets.